Literature DB >> 27152240

Extracellular PKM2 induces cancer proliferation by activating the EGFR signaling pathway.

Ming-Chuan Hsu1, Wen-Chun Hung2, Hirohito Yamaguchi3, Seung-Oe Lim3, Hsin-Wei Liao3, Chia-Hua Tsai2, Mien-Chie Hung4.   

Abstract

Pyruvate kinase is a key enzyme in the glycolytic pathway that converts phosphoenolpyruvate to pyruvate, and the M2 isoform of pyruvate kinase (PKM2) is associated with cancer. PKM2 has been reported to function independently of its pyruvate kinase activity, which is crucial for cancer cell proliferation. Moreover, there is growing evidence indicating that dimeric PKM2 is released from tumor cells into the circulation of cancer patients. However, the role of secreted PKM2 in cancer is not well understood. Here, we found that the phosphorylation level of epidermal growth factor receptor (EGFR) significantly increased upon the exposure of cells to the recombinant PKM2 protein. In addition, secreted PKM2 induces EGFR phosphorylation and activates the EGFR downstream signaling in triple-negative breast cancer cells. In contrast, knocking down PKM2 decreased EGFR phosphorylation. Moreover, expression of R399E mutant PKM2, which has been reported to preferentially form a dimer, enhanced EGFR phosphorylation, cellular transformation, and cell proliferation more strongly than the wild-type PKM2. Thus, our study revealed a novel function of extracellular PKM2 in the promoting cancer cell proliferation through EGFR activation.

Entities:  

Keywords:  EGFR; PKM2; triple-negative breast cancer

Year:  2016        PMID: 27152240      PMCID: PMC4851842     

Source DB:  PubMed          Journal:  Am J Cancer Res        ISSN: 2156-6976            Impact factor:   6.166


  39 in total

1.  Pyruvate kinase M2 regulates gene transcription by acting as a protein kinase.

Authors:  Xueliang Gao; Haizhen Wang; Jenny J Yang; Xiaowei Liu; Zhi-Ren Liu
Journal:  Mol Cell       Date:  2012-02-02       Impact factor: 17.970

2.  EGFR Signaling Enhances Aerobic Glycolysis in Triple-Negative Breast Cancer Cells to Promote Tumor Growth and Immune Escape.

Authors:  Seung-Oe Lim; Chia-Wei Li; Weiya Xia; Heng-Huan Lee; Shih-Shin Chang; Jia Shen; Jennifer L Hsu; Daniel Raftery; Danijel Djukovic; Haiwei Gu; Wei-Chao Chang; Hung-Ling Wang; Mong-Liang Chen; Longfei Huo; Chung-Hsuan Chen; Yun Wu; Aysegul Sahin; Samir M Hanash; Gabriel N Hortobagyi; Mien-Chie Hung
Journal:  Cancer Res       Date:  2016-01-12       Impact factor: 12.701

3.  MET is a potential target for use in combination therapy with EGFR inhibition in triple-negative/basal-like breast cancer.

Authors:  Yu Jin Kim; Jong-Sun Choi; Jinwon Seo; Ji-Young Song; Seung Eun Lee; Mi Jung Kwon; Mi Jeong Kwon; Juthika Kundu; Kyungsoo Jung; Ensel Oh; Young Kee Shin; Yoon-La Choi
Journal:  Int J Cancer       Date:  2014-05-15       Impact factor: 7.396

4.  Epidermal growth factor receptor protein overexpression and gene amplification are associated with aggressive biological behaviors of esophageal squamous cell carcinoma.

Authors:  Gang Lin; Xiao-Jiang Sun; Qian-Bo Han; Zhun Wang; Ya-Ping Xu; Jia-Lei Gu; Wei Wu; G U Zhang; Jin-Lin Hu; Wen-Yong Sun; Wei-Min Mao
Journal:  Oncol Lett       Date:  2015-05-27       Impact factor: 2.967

Review 5.  Regulation and function of pyruvate kinase M2 in cancer.

Authors:  Weiwei Yang; Zhimin Lu
Journal:  Cancer Lett       Date:  2013-06-18       Impact factor: 8.679

Review 6.  Regulation of cancer cell metabolism.

Authors:  Rob A Cairns; Isaac S Harris; Tak W Mak
Journal:  Nat Rev Cancer       Date:  2011-02       Impact factor: 60.716

7.  Marker for renal cell carcinoma (RCC): the dimeric form of pyruvate kinase type M2 (Tu M2-PK).

Authors:  H W Wechsel; E Petri; K H Bichler; G Feil
Journal:  Anticancer Res       Date:  1999 Jul-Aug       Impact factor: 2.480

8.  Invasive ductal carcinoma of the breast with the "triple-negative" phenotype: prognostic implications of EGFR immunoreactivity.

Authors:  Giuseppe Viale; Nicole Rotmensz; Patrick Maisonneuve; Luca Bottiglieri; Emilia Montagna; Alberto Luini; Paolo Veronesi; Mattia Intra; Rosalba Torrisi; Anna Cardillo; Elisabetta Campagnoli; Aron Goldhirsch; Marco Colleoni
Journal:  Breast Cancer Res Treat       Date:  2008-10-07       Impact factor: 4.872

9.  Pyruvate kinase M2 in blood circulation facilitates tumor growth by promoting angiogenesis.

Authors:  Liangwei Li; Yinwei Zhang; Jingjuan Qiao; Jenny J Yang; Zhi-Ren Liu
Journal:  J Biol Chem       Date:  2014-07-28       Impact factor: 5.157

10.  Antagonism of EGFR and HER3 enhances the response to inhibitors of the PI3K-Akt pathway in triple-negative breast cancer.

Authors:  Jessica J Tao; Pau Castel; Nina Radosevic-Robin; Moshe Elkabets; Neil Auricchio; Nicola Aceto; Gregory Weitsman; Paul Barber; Borivoj Vojnovic; Haley Ellis; Natasha Morse; Nerissa Therese Viola-Villegas; Ana Bosch; Dejan Juric; Saswati Hazra; Sharat Singh; Phillip Kim; Anna Bergamaschi; Shyamala Maheswaran; Tony Ng; Frédérique Penault-Llorca; Jason S Lewis; Lisa A Carey; Charles M Perou; José Baselga; Maurizio Scaltriti
Journal:  Sci Signal       Date:  2014-03-25       Impact factor: 8.192

View more
  18 in total

1.  Polypyrimidine Tract-Binding Protein 1 promotes proliferation, migration and invasion in clear-cell renal cell carcinoma by regulating alternative splicing of PKM.

Authors:  Junyi Jiang; Xu Chen; Hao Liu; Jing Shao; Ruihui Xie; Peng Gu; Chaohui Duan
Journal:  Am J Cancer Res       Date:  2017-02-01       Impact factor: 6.166

Review 2.  A critical review of the role of M2PYK in the Warburg effect.

Authors:  Robert A Harris; Aron W Fenton
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2019-01-29       Impact factor: 10.680

3.  Plasma Pyruvate Kinase M2 as a marker of vascular inflammation in giant cell arteritis.

Authors:  Idil Esen; William F Jiemy; Yannick van Sleen; Johan Bijzet; Daniel M de Jong; Pieter H Nienhuis; Riemer H J A Slart; Peter Heeringa; Annemieke M H Boots; Elisabeth Brouwer
Journal:  Rheumatology (Oxford)       Date:  2022-07-06       Impact factor: 7.046

Review 4.  Altered Mitochondrial Signalling and Metabolism in Cancer.

Authors:  Esita Chattopadhyay; Bidyut Roy
Journal:  Front Oncol       Date:  2017-03-20       Impact factor: 6.244

5.  Influenza Virus Infection Induces Host Pyruvate Kinase M Which Interacts with Viral RNA-Dependent RNA Polymerase.

Authors:  Yukari Miyake; Kosuke Ishii; Ayae Honda
Journal:  Front Microbiol       Date:  2017-02-09       Impact factor: 5.640

Review 6.  PKM2 in carcinogenesis and oncotherapy.

Authors:  Xia He; Suya Du; Tiantian Lei; Xiang Li; Yilong Liu; Hailian Wang; Rongsheng Tong; Yi Wang
Journal:  Oncotarget       Date:  2017-11-20

7.  Clinicopathological and prognostic significance of PKM2 protein expression in cirrhotic hepatocellular carcinoma and non-cirrhotic hepatocellular carcinoma.

Authors:  Yan Liu; Hao Wu; Ying Mei; Xiong Ding; Xiaoli Yang; Changping Li; Mingming Deng; Jianping Gong
Journal:  Sci Rep       Date:  2017-11-10       Impact factor: 4.379

8.  Gene expression association study in feline mammary carcinomas.

Authors:  Daniela Ferreira; Bárbara Martins; Maria Soares; Jorge Correia; Filomena Adega; Fernando Ferreira; Raquel Chaves
Journal:  PLoS One       Date:  2019-08-28       Impact factor: 3.240

9.  Overexpression of Pyruvate Kinase Type M2 (PKM2) Promotes Ovarian Cancer Cell Growth and Survival Via Regulation of Cell Cycle Progression Related with Upregulated CCND1 and Downregulated CDKN1A Expression.

Authors:  Bin Zheng; Fangfang Liu; Li Zeng; Li Geng; Xiaojuan Ouyang; Kai Wang; Qiaojia Huang
Journal:  Med Sci Monit       Date:  2018-05-12

Review 10.  Pyruvate kinase M2 fuels multiple aspects of cancer cells: from cellular metabolism, transcriptional regulation to extracellular signaling.

Authors:  Ming-Chuan Hsu; Wen-Chun Hung
Journal:  Mol Cancer       Date:  2018-02-19       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.